CTSO Cytosorbents Corporation
Healthcare$0.46+0.39%ClosedMarket Cap: $29.0M
As of 2026-05-26
Valuation
P/E (TTM)
—
PEG
—
P/B
13.18
P/S
0.78
EV/EBITDA
-6.22
DCF Value
$-5.20
FCF Yield
-35.3%
Div Yield
0.0%
Margins & Returns
Gross Margin
71.0%
Operating Margin
-36.0%
Net Margin
-31.9%
ROE
-165.1%
ROA
-29.2%
ROIC
-41.2%
Income Statement
Periods shown are fiscal year quarters (may differ from calendar year)
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q1 null | $8.9M | 69.2% | $-3.0M | $-5.1M | $— | — |
| Q4 null | $9.2M | 73.7% | $-3.9M | $-5.5M | $— | — |
| FY null | $37.1M | 71.5% | $-14.2M | $-8.2M | $— | — |
| Q3 null | $9.5M | 70.3% | $-2.9M | $-3.2M | $— | — |
| Q2 null | $9.6M | 70.9% | $-3.6M | $1.9M | $— | — |
| Q1 null | $8.7M | 71.1% | $-3.9M | $-1.5M | $— | — |
| Q4 null | $9.2M | 102.7% | $-4.0M | $-7.9M | $— | — |
| FY null | $35.6M | 69.9% | $-16.5M | $-20.7M | $— | — |
| Q3 null | $8.6M | 52.3% | $-4.4M | $-2.3M | $— | — |
| Q2 null | $8.8M | 73.5% | $-3.6M | $-4.3M | $— | — |
| Q1 null | $9.0M | 76.5% | $-4.7M | $-6.1M | $— | — |
| Q4 2023 | $7.3M | 68.1% | $-9.6M | $-6.1M | $-0.13 | — |